Does vitamin K2 (MK-7) keep calcium out of arteries and extend healthy life?
Claim attributed to Supplement industry (e.g. MenaQ7/NattoPharma marketing) and some functional-medicine figures , Promoted by makers of branded MK-7 (MenaQ7) and functional-medicine influencers; leans on a real mechanism plus one diet cohort while downplaying the null calcification trial.
The biochemistry is genuine and MK-7 reliably activates the calcium-handling proteins, but the only randomized trial on a hard calcification endpoint was null and the longevity claim is untested. Plausible mechanism, encouraging surrogates, no proof of disease prevention.
It reliably moves a blood marker in weeks; it has never been shown to keep a real artery clear or make a person live longer, and the one hard test came back null.
What it’s supposed to target
- Matrix Gla protein (MGP)
- Osteocalcin / bone binding
- Arterial calcification
- Calcium “traffic” theory
Vitamin K2 is a required cofactor for an enzyme that carboxylates two key proteins: matrix Gla protein (MGP), which when active blocks calcium from depositing in artery walls, and osteocalcin, which helps bind calcium into bone. The tidy theory follows: enough K2 directs calcium traffic correctly, keeping it in bones and out of arteries, so supplementing should harden bone and soften the arterial stiffening that drives cardiovascular aging.
The mechanism is real and elegant, and observational data (notably the Rotterdam Study) link higher K2 intake to less coronary calcification. But the controlled trials have mostly underdelivered on hard endpoints. A three-year MK-7 trial showed only a modest arterial-stiffness benefit, and a randomized trial (AVADEC) found K2 plus vitamin D did not slow aortic-valve calcification at all. Bone-fracture evidence is mixed and strongest for a high-dose form (MK-4) used in Japan, not the MK-7 sold as a supplement. A strong mechanism and suggestive epidemiology, running ahead of trial proof.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
K2 activates MGP and osteocalcin: holds, established biochemistry.
Lowering dp-ucMGP slows real calcification on imaging: does not hold, the AVADEC trial was null.
Less calcification cuts cardiovascular events: untested, no event trial exists.
That translates into longer healthy life: untested, no longevity data.
What the evidence actually shows
The mechanism is real; the hard endpoint was not met
Vitamin K is an essential cofactor for carboxylating matrix Gla protein (MGP), a potent local inhibitor of vascular calcification, and osteocalcin in bone. MK-7 efficiently reaches arteries and cuts inactive dp-ucMGP by roughly 50% (Knapen 2015), so the rationale that K2 keeps calcium 'in bone and out of arteries' is biologically sound. But the decisive test, the randomized AVADEC trial (Diederichsen, Circulation 2022; n=365 men, 720 ug MK-7 plus vitamin D, 2 years), found no significant slowing of aortic valve calcification, its pre-specified primary outcome. The lead author said they were 'surely disappointed.'
Supportive data are observational or surrogate, and longevity is untested
The encouraging cardiovascular signals are soft. The Rotterdam Study (n=4807, dietary intake) linked the highest menaquinone intake to ~41% lower coronary heart disease and less aortic calcification, but it is a food cohort, confounding-prone and not causal. Knapen 2015 improved arterial stiffness, a surrogate marker rather than a clinical event, and came from VitaK/Maastricht using the manufacturer's MenaQ7. For bone, a 2022 meta-analysis found K2-alone did not significantly raise spine BMD; the fracture benefit traced to Japanese high-dose MK-4 drug trials. No RCT shows MK-7 cuts heart attacks, strokes, CV death, or extends lifespan.
Studies, graded, and who paid
Established biochemistry; MK-7 reliably cuts inactive MGP versus placebo.
The one hard-endpoint RCT (AVADEC, aortic valve) was null; only soft surrogates moved.
No trial has measured heart attacks, strokes, CV death, or all-cause mortality.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 2 | Knapen 2015, MK-7 arterial stiffness RCT | 3-yr double-blind RCT, surrogate endpoint, n=244 | n=244 | Industry-funded VitaK/Maastricht, tied to NattoPharma; used branded MenaQ7. | Surrogate (arterial stiffness), not clinical events; manufacturer link. |
| 3 | AVADEC (Diederichsen 2022), aortic valve calcification | 2-yr double-blind RCT, hard imaging endpoint, n=365 | n=365 | Mixed Independent Danish academic design; ingredient from Kappa Bioscience (K2Vital), not MenaQ7. | Null primary outcome; men only; coronary-calcium hint was exploratory. |
| 1 | Rotterdam Study (Geleijnse 2004), dietary K2 and CHD | Prospective observational cohort, n=4807 | n=4807 | Funding unknown Academic Dutch cohort; original funding not confirmed from opened source. | Dietary intake, confounding-prone, not causal; not replicated cleanly. |
| 5 | Ma 2022, K2 and postmenopausal osteoporosis | Systematic review/meta-analysis, 16 RCTs, 6425 | 16 RCTs; 6425 | Independent Chinese academic grants; independent of K2 supplement industry. | K2-alone not significant for BMD; fracture signal driven by Japanese MK-4. |
The favourable cardiovascular RCT clusters around the MK-7 manufacturer ecosystem, while the independent hard-endpoint trial came back null, the central credibility tension.
Unproven ≠ disproven
The longevity and cardiovascular-event half of the claim is untested, not disproven: no trial has measured hard clinical outcomes for MK-7.
Where claim and evidence diverge
Strong mechanism and biomarker change, but the leap from a falling blood marker to less real calcification, fewer events, and longer life is exactly where the evidence runs out or turns null.
The money trail
Branded MK-7 (MenaQ7) is sold by NattoPharma/Gnosis, and much 'K2 cleans arteries' messaging traces to that supply chain; the positive Knapen trial came from manufacturer-linked VitaK.
The null AVADEC trial used a different supplier (Kappa Bioscience) under independent academic design; the bone-fracture benefit rests on Japanese MK-4 prescription drugs, not OTC MK-7.
The honest read
K2 is safe and the calcium-routing biochemistry is real, but 'prevents arterial calcification and extends healthy life' overstates what trials show: the one hard test was null and longevity has never been measured.
What would change this verdict
An adequately powered, independent RCT showing MK-7 slows arterial or valve calcification on CT versus placebo.
An RCT showing MK-7 reduces cardiovascular events or all-cause mortality.
Sources
- Geleijnse JM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134(11):3100-5.
- Knapen MHJ, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thromb Haemost. 2015;113(5):1135-44.
- Diederichsen ACP, et al. Vitamin K2 and D in Patients With Aortic Valve Calcification (AVADEC). Circulation. 2022;145(18):1387-1397.
- American Heart Association News. Despite hopes, vitamin K2 supplements fail to slow calcium buildup in heart valve. April 25, 2022.
- Ma ML, et al. Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: a systematic review and meta-analysis of RCTs. Front Public Health. 2022;10:979649.
People also ask
- Does vitamin K2 clear calcium from your arteries?
- Not proven. The one hard-endpoint randomized trial, AVADEC on the aortic valve, was null; only soft surrogate markers moved. The calcium-routing biochemistry is real, but a falling blood marker has not translated into less actual calcification.
- What does MK-7 actually do in the body?
- MK-7 reliably activates the calcium-handling proteins MGP and osteocalcin, cutting inactive MGP (dp-ucMGP) by roughly 50 percent versus placebo. This is established biochemistry, but activating these proteins has not been shown to prevent disease.
- Can vitamin K2 help you live longer?
- There is no evidence for that. No trial has measured heart attacks, strokes, cardiovascular death, or all-cause mortality on MK-7. The longevity claim is untested, so 'extends healthy life' overstates what the trials show.
- Is the K2 bone benefit the same as the supplements sold online?
- Not necessarily. The bone-fracture benefit rests on Japanese MK-4 prescription drugs, not over-the-counter MK-7 supplements. Much 'K2 cleans arteries' marketing traces to branded MK-7 supply chains, while the null hard-endpoint trial used independent academic design.
Part of our guide: Longevity supplements, fact-checked
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.